Literature DB >> 22588159

Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung cancer transformation in the same patient.

Vincent Fallet1, Anne-Marie Ruppert, Virginie Poulot, Roger Lacave, Laure Belmont, Martine Antoine, Jacques Cadranel, Marie Wislez, Armelle Lavolé.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22588159     DOI： 10.1097/JTO.0b013e31824fea45

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  6 in total

1.  Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma.

Authors:  Greta Alì; Rossella Bruno; Mirella Giordano; Irene Prediletto; Letizia Marconi; Simonetta Zupo; Franco Fedeli; Alessandro Ribechini; Antonio Chella; Gabriella Fontanini
Journal:  Oncol Lett       Date:  2016-09-26       Impact factor: 2.967

2.  Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.

Authors:  Kenichi Suda; Isao Murakami; Kazuko Sakai; Hiroshi Mizuuchi; Shigeki Shimizu; Katsuaki Sato; Kenji Tomizawa; Shuta Tomida; Yasushi Yatabe; Kazuto Nishio; Tetsuya Mitsudomi
Journal:  Sci Rep       Date:  2015-09-24       Impact factor: 4.379

Review 3.  Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy.

Authors:  Marzia Del Re; Stefania Crucitta; Giulia Gianfilippo; Antonio Passaro; Iacopo Petrini; Giuliana Restante; Angela Michelucci; Stefano Fogli; Filippo de Marinis; Camillo Porta; Antonio Chella; Romano Danesi
Journal:  Int J Mol Sci       Date:  2019-08-14       Impact factor: 5.923

4.  Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment.

Authors:  Julie A Vendrell; Xavier Quantin; Isabelle Serre; Jérôme Solassol
Journal:  Ther Adv Med Oncol       Date:  2020-12-18       Impact factor: 8.168

5.  Outcomes in Patients With Lung Adenocarcinoma With Transformation to Small Cell Lung Cancer After EGFR Tyrosine Kinase Inhibitors Resistance: A Systematic Review and Pooled Analysis.

Authors:  Jinhe Xu; Lihuan Xu; Baoshan Wang; Wencui Kong; Ying Chen; Zongyang Yu
Journal:  Front Oncol       Date:  2022-01-28       Impact factor: 6.244

6.  A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity.

Authors:  Yanjun Xu; Zhiyu Huang; Lei Gong; Yun Fan
Journal:  Anticancer Drugs       Date:  2017-10       Impact factor: 2.248
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.